Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer.

Research output: Contribution to journalArticle

Standard

Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. / Bauden, Monika; Pamart, Dorian; Ansari, Daniel; Herzog, Marielle; Eccleston, Mark; Micallef, Jake; Andersson, Bodil; Andersson, Roland.

In: Clinical Epigenetics, Vol. 7, 106, 2015.

Research output: Contribution to journalArticle

Harvard

APA

CBE

MLA

Vancouver

Author

Bauden, Monika ; Pamart, Dorian ; Ansari, Daniel ; Herzog, Marielle ; Eccleston, Mark ; Micallef, Jake ; Andersson, Bodil ; Andersson, Roland. / Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer. In: Clinical Epigenetics. 2015 ; Vol. 7.

RIS

TY - JOUR

T1 - Circulating nucleosomes as epigenetic biomarkers in pancreatic cancer.

AU - Bauden, Monika

AU - Pamart, Dorian

AU - Ansari, Daniel

AU - Herzog, Marielle

AU - Eccleston, Mark

AU - Micallef, Jake

AU - Andersson, Bodil

AU - Andersson, Roland

PY - 2015

Y1 - 2015

N2 - To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging due to nonspecific elevation in sera of patients with benign diseases. Here, we report for the first time differential, disease-associated epigenetic profiles of intact cell-free nucleosomes (cfnucleosomes) containing specific DNA and histone modifications as well as histone variants circulating in the blood. The study comprised serum samples from 59 individuals, including 25 patients with resectable pancreatic cancer, 10 patients with benign pancreatic disease, and 24 healthy individuals using Nucleosomics(®), a novel ELISA method.

AB - To improve the prognosis of patients with pancreatic cancer, new biomarkers are required for earlier, pre-symptomatic diagnosis. Epigenetic mutations take place at the earliest stages of tumorigenesis and therefore offer new approaches for detecting and diagnosing disease. Nucleosomes are the repeating subunits of DNA and histone proteins that constitute human chromatin. Because of their release into the circulation, intact nucleosome levels in serum or plasma can serve as diagnostic disease biomarkers, and elevated levels have been reported in various cancers. However, quantifying nucleosomes in the circulation for cancer detection has been challenging due to nonspecific elevation in sera of patients with benign diseases. Here, we report for the first time differential, disease-associated epigenetic profiles of intact cell-free nucleosomes (cfnucleosomes) containing specific DNA and histone modifications as well as histone variants circulating in the blood. The study comprised serum samples from 59 individuals, including 25 patients with resectable pancreatic cancer, 10 patients with benign pancreatic disease, and 24 healthy individuals using Nucleosomics(®), a novel ELISA method.

U2 - 10.1186/s13148-015-0139-4

DO - 10.1186/s13148-015-0139-4

M3 - Article

VL - 7

JO - Clinical Epigenetics

JF - Clinical Epigenetics

SN - 1868-7075

M1 - 106

ER -